Serum Marker Predicts Cardiovascular Events in Diabetes
Elevated serum level of free light chains linked to adverse CV outcomes in type 2 diabetes.
Elevated levels of polyclonal serum immunoglobulin combined free light chains (cFLCs) may indicate adverse cardiovascular disease (CVD) outcomes in patients with type 2 diabetes, according to study findings published online in Diabetes Care.
Srikanth Bellary, MBBS, of Aston University in Birmingham, U.K., and colleagues conducted a cohort study of 352 South Asian patients with type 2 diabetes to assess the association between cFLCs and cardiovascular disease events. Among patients with type 2 diabetes who had CVD events during two years of follow-up, cFLC levels were significantly elevated in 8% (50.7 vs. 42.8 mg/L). On multivariable analysis, elevated cFLC level (greater than 57.2 mg/L) was associated with a significant 3-fold increased odds of adverse CVD outcomes. This association remained significant after adjustment for age, albumin-to-creatinine ratio, diabetes duration, or treatment.
"cFLC elevation is a novel marker for CVD outcomes in type 2 diabetes that warrants further investigation," the authors wrote.